[Translation] A 24-month placebo-controlled, double-blind, parallel-group study evaluating the efficacy and safety of E2609 in subjects with early-stage Alzheimer's disease
本研究的主要目的是根据早期阿尔茨海默症 (EAD) 受试者在第 24 个月时临床痴呆综合汇总评定量表 (CDR-SB) 评分相比基线的变化,确定 E2609是否优于安慰剂。
[Translation] The primary objective of this study was to determine whether E2609 was superior to placebo based on the change from baseline in the Clinical Dementia Summary Rating Scale (CDR-SB) score at month 24 in subjects with early Alzheimer's disease (EAD) agent.